EDSA Quote, Financials, Valuation and Earnings

ESSA Pharma has a net margin of -- compared to Edesa Biotech's net margin of --. Edesa Biotech's return on equity of -- beat ESSA Pharma's return on equity of --.

Edesa Biotech has a consensus price target of $10.33, signalling upside risk potential of 357.23%. On the other hand ESSA Pharma has an analysts' consensus of $1.68 which suggests that it could fall by -9.61%. Given that Edesa Biotech has higher upside potential than ESSA Pharma, analysts believe Edesa Biotech is more attractive than ESSA Pharma.

Edesa Biotech has a beta of 0.393, which suggesting that the stock is 60.718% less volatile than S&P 500. In comparison ESSA Pharma has a beta of 1.559, suggesting its more volatile than the S&P 500 by 55.914%.

Edesa Biotech has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ESSA Pharma offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Edesa Biotech pays -- of its earnings as a dividend. ESSA Pharma pays out -- of its earnings as a dividend.

Edesa Biotech quarterly revenues are --, which are smaller than ESSA Pharma quarterly revenues of --. Edesa Biotech's net income of -$1.6M is higher than ESSA Pharma's net income of -$6.4M. Notably, Edesa Biotech's price-to-earnings ratio is -- while ESSA Pharma's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Edesa Biotech is 25.98x versus -- for ESSA Pharma. Usually stocks with elevated PS ratios are considered overvalued.

Lexaria Bioscience has a net margin of -- compared to Edesa Biotech's net margin of -2177.64%. Edesa Biotech's return on equity of -- beat Lexaria Bioscience's return on equity of -147.06%.

Edesa Biotech has a consensus price target of $10.33, signalling upside risk potential of 357.23%. On the other hand Lexaria Bioscience has an analysts' consensus of $6.33 which suggests that it could grow by 627.97%. Given that Lexaria Bioscience has higher upside potential than Edesa Biotech, analysts believe Lexaria Bioscience is more attractive than Edesa Biotech.

Edesa Biotech has a beta of 0.393, which suggesting that the stock is 60.718% less volatile than S&P 500. In comparison Lexaria Bioscience has a beta of 0.892, suggesting its less volatile than the S&P 500 by 10.756%.

Edesa Biotech has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Lexaria Bioscience offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Edesa Biotech pays -- of its earnings as a dividend. Lexaria Bioscience pays out -- of its earnings as a dividend.

Edesa Biotech quarterly revenues are --, which are smaller than Lexaria Bioscience quarterly revenues of $174K. Edesa Biotech's net income of -$1.6M is higher than Lexaria Bioscience's net income of -$3.8M. Notably, Edesa Biotech's price-to-earnings ratio is -- while Lexaria Bioscience's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Edesa Biotech is 25.98x versus 24.08x for Lexaria Bioscience. Usually stocks with elevated PS ratios are considered overvalued.

ProMIS Neurosciences has a net margin of -- compared to Edesa Biotech's net margin of --. Edesa Biotech's return on equity of -- beat ProMIS Neurosciences's return on equity of --.

Edesa Biotech has a consensus price target of $10.33, signalling upside risk potential of 357.23%. On the other hand ProMIS Neurosciences has an analysts' consensus of $5.34 which suggests that it could grow by 1087.17%. Given that ProMIS Neurosciences has higher upside potential than Edesa Biotech, analysts believe ProMIS Neurosciences is more attractive than Edesa Biotech.

Edesa Biotech has a beta of 0.393, which suggesting that the stock is 60.718% less volatile than S&P 500. In comparison ProMIS Neurosciences has a beta of -0.097, suggesting its less volatile than the S&P 500 by 109.722%.

Edesa Biotech has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ProMIS Neurosciences offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Edesa Biotech pays -- of its earnings as a dividend. ProMIS Neurosciences pays out -- of its earnings as a dividend.

Edesa Biotech quarterly revenues are --, which are smaller than ProMIS Neurosciences quarterly revenues of --. Edesa Biotech's net income of -$1.6M is higher than ProMIS Neurosciences's net income of -$7.3M. Notably, Edesa Biotech's price-to-earnings ratio is -- while ProMIS Neurosciences's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Edesa Biotech is 25.98x versus -- for ProMIS Neurosciences. Usually stocks with elevated PS ratios are considered overvalued.

Xenon Pharmaceuticals has a net margin of -- compared to Edesa Biotech's net margin of -867.29%. Edesa Biotech's return on equity of -- beat Xenon Pharmaceuticals's return on equity of -31.52%.

Edesa Biotech has a consensus price target of $10.33, signalling upside risk potential of 357.23%. On the other hand Xenon Pharmaceuticals has an analysts' consensus of $55.23 which suggests that it could grow by 74.68%. Given that Edesa Biotech has higher upside potential than Xenon Pharmaceuticals, analysts believe Edesa Biotech is more attractive than Xenon Pharmaceuticals.

Edesa Biotech has a beta of 0.393, which suggesting that the stock is 60.718% less volatile than S&P 500. In comparison Xenon Pharmaceuticals has a beta of 1.098, suggesting its more volatile than the S&P 500 by 9.839%.

Edesa Biotech has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xenon Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Edesa Biotech pays -- of its earnings as a dividend. Xenon Pharmaceuticals pays out -- of its earnings as a dividend.

Edesa Biotech quarterly revenues are --, which are smaller than Xenon Pharmaceuticals quarterly revenues of $7.5M. Edesa Biotech's net income of -$1.6M is higher than Xenon Pharmaceuticals's net income of -$65M. Notably, Edesa Biotech's price-to-earnings ratio is -- while Xenon Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Edesa Biotech is 25.98x versus 175.06x for Xenon Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.